Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Open accessAbstract
The development of cancer vaccines has been intensively pursued over the past 50 years with modest success. However, recent advancements in the fields of genetics, molecular biology, biochemistry, and immunology have renewed interest in these immunotherapies and allowed the development of promising cancer vaccine candidates. Numerous clinical trials testing the response evoked by tumour antigens, differing in origin and nature, have shed light on the desirable target characteristics capable of inducing strong tumour-specific non-toxic responses with increased potential to bring clinical benefit to patients. Novel delivery methods, ranging from a patient’s autologous dendritic cells to liposome nanoparticles, have exponentially increased the abundance and exposure of the antigenic payloads. Furthermore, growing knowledge of the mechanisms by which tumours evade the immune response has led to new approaches to reverse these roadblocks and to re-invigorate previously suppressed anti-tumour surveillance. The use of new drugs in combination with antigen-based therapies is highly targeted and may represent the future of cancer vaccines. In this review, we address the main antigens and delivery methods used to develop cancer vaccines, their clinical outcomes, and the new directions that the vaccine immunotherapy field is taking.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [351]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,380 · see citing works
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
Mosmann, T. R., & Coffman, R. L. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.001045 · Cited by 7,692 · see citing works
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,822 · see citing works
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · see citing works
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El‐Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,384 · see citing works
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,803 · see citing works
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,594 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420 · see citing works
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · see citing works
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works
Mucins in cancer: protection and control of the cell surface
Hollingsworth, M. A., & Swanson, B. J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1251 · Cited by 1,813 · see citing works
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, Á., Eidinger, D., & Bruce, A. W. (1976) · The Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,796 · see citing works
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · see citing works
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,720 · see citing works
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608 · see citing works
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587 · see citing works
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581 · see citing works
Jurtz, V. I., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,476 · see citing works
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · see citing works
Cohen, E., Soulières, D., le Tourneau, C., Dinis, J., Licitra, L., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,423 · see citing works
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., Arunachalam, P. S., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,417 · see citing works
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,391 · see citing works
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388 · see citing works
CD4 <sup>+</sup> T Cells: Differentiation and Functions
Luckheeram, R. V., Zhou, R., Verma, A. D., & Xia, B. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/925135 · Cited by 1,381 · see citing works
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285 · see citing works
Immunity to Methylcholanthrene-Induced Sarcomas
Prehn, R. T., & Main, J. M. (1957) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,230 · see citing works
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,229 · see citing works
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191 · see citing works
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., den Eynde, B. J. V., van der Bruggen, P., & Boon, T. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3670 · Cited by 1,142 · see citing works
Szmuness, W., Stevens, C. E., Harley, E. J., Zang, E. A., Oleszko, W. R., William, D. C., D, R. S. M., Morrison, J. M., & Kellner, A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198010093031501 · Cited by 1,117 · see citing works
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108 · see citing works
Functional amyloid – from bacteria to humans
Fowler, D. M., Koulov, A. V., Balch, W. E., & Kelly, J. W. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.03.003 · Cited by 1,052 · see citing works
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052 · see citing works
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042 · see citing works
T and Tn, General Carcinoma Autoantigens
Springer, G. F. (1984) · Science · doi:10.1126/science.6729450 · Cited by 1,009 · see citing works
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997 · see citing works
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965 · see citing works
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938 · see citing works
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2016) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 926 · see citing works
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J. S., Gailani, F., Riley, L. B., Conlon, K. C., Pockaj, B. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 913 · see citing works
Molecular biology of hepatitis B virus infection
Seeger, C., & Mason, W. S. (2015) · Virology · doi:10.1016/j.virol.2015.02.031 · Cited by 868 · see citing works
MUC1: a multifaceted oncoprotein with a key role in cancer progression
Nath, S., & Mukherjee, P. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.02.007 · Cited by 837 · see citing works
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J. J., Yuh, L., Provost, N. M., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 809 · see citing works
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P., de Vries, I. D., Torensma, R., & Figdor, C. (2007) · Nature reviews. Immunology · doi:10.1038/nri2173 · Cited by 791 · see citing works
Thompson, M. P., & Kurzrock, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0670-3 · Cited by 787 · see citing works
Hausen, H. Z. (1991) · Science · doi:10.1126/science.1659743 · Cited by 783 · see citing works
Gaugler, B., den Eynde, B. V., van der Bruggen, P., et al. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.3.921 · Cited by 767 · see citing works
Loeb, L. A., Loeb, K. R., & Anderson, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334858100 · Cited by 762 · see citing works
Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M. J., Yan, J., Edwards, L., Parker, R. L., Denny, L., Giffear, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00239-1 · Cited by 732 · see citing works
Jäger, E., Chen, Y., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jäger, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.2.265 · Cited by 725 · see citing works
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Montoto, S. S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 672 · see citing works
Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
Small, E. J., Fratesi, P., Reese, D., Strang, G., Laus, R., Peshwa, M. V., & Valone, F. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3894 · Cited by 625 · see citing works
A neoantigen fitness model predicts tumor response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V., Hellmann, M., Solovyov, A., Rizvi, N., Merghoub, T., Levine, A., Chan, T., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 624 · see citing works
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Pal, A., & Kundu, R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03116 · Cited by 615 · see citing works
Systematic analysis of telomere length and somatic alterations in 31 cancer types
Barthel, F. P., Wei, W., Tang, M., Martinez-Ledesma, E., Hu, X., Amin, S. B., Akdemir, K. C., Seth, S., Song, X., Wang, Q., et al. (2017) · Nature Genetics · doi:10.1038/ng.3781 · Cited by 614 · see citing works
Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611 · see citing works
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 608 · see citing works
Bakker, A. B. H., Schreurs, M. W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.3.1005 · Cited by 589 · see citing works
Nanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582 · see citing works
Epidemiology and burden of HPV-related disease
Serrano, B., Brotons, M., Bosch, F. X., et al. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.08.006 · Cited by 564 · see citing works
Shi, Y., Liu, C. H., Roberts, A. I., Das, J., Xu, G., Ren, G., Zhang, Y., Zhang, L., Yuan, Z., Tan, H. S., et al. (2006) · Cell Research · doi:10.1038/sj.cr.7310017 · Cited by 550 · see citing works
Farrell, P. J. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013023 · Cited by 542 · see citing works
Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse
Old, L. J., Clarke, D. A., & Benacerraf, B. (1959) · Nature · doi:10.1038/184291a0 · Cited by 539 · see citing works
Butts, C. A., Socinski, M. A., Mitchell, P. L. R., Thatcher, N., Havel, L., Krzakowski, M. J., Nawrocki, S., Ciuleanu, T., Bosquée, L., Trigo, J. M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 539 · see citing works
Vansteenkiste, J., Cho, B. C., Vanakesa, T., Pas, T. M. D., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 512 · see citing works
Engineering dendritic cell vaccines to improve cancer immunotherapy
Perez, C. R., & Palma, M. D. (2019) · Nature Communications · doi:10.1038/s41467-019-13368-y · Cited by 507 · see citing works
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Vermorken, J. B., Claessen, A. M. E., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J. L. M., Bloemena, E., Ransom, J. H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07186-4 · Cited by 504 · see citing works
Cong, Y. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.1.137 · Cited by 485 · see citing works
The testis in immune privilege
Fijak, M., & Meinhardt, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00438.x · Cited by 483 · see citing works
MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases
Doyle, J., Gao, J., Wang, J., Yang, M., & Potts, P. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.029 · Cited by 468 · see citing works
Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections
Odumade, O. A., Hogquist, K. A., & Balfour, H. H. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00044-10 · Cited by 457 · see citing works
Survivin: a unique target for tumor therapy
Garg, H., Suri, P., Gupta, J. C., Talwar, G. P., & Dubey, S. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0326-1 · Cited by 442 · see citing works
Kufe, D. W. (2012) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 440 · see citing works
HPV vaccines – A review of the first decade
Harper, D. M., & DeMars, L. R. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.004 · Cited by 431 · see citing works
Pardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 431 · see citing works
Toll-like receptor 8 senses degradation products of single-stranded RNA
Tanji, H., Ohto, U., Shibata, T., Taoka, M., Yamauchi, Y., Isobe, T., Miyake, K., & Shimizu, T. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2943 · Cited by 404 · see citing works
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors
Valentijn, L. J., Köster, J., Zwijnenburg, D. A., Hasselt, N. E., Sluis, P. V., Volckmann, R., van Noesel, M. M., George, R. E., Tytgat, G. A. M., Molenaar, J. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3438 · Cited by 398 · see citing works
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al‐Khadairi, G., Roelands, J. P., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 394 · see citing works
Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase
Pineda, C. T., Ramanathan, S., Fon Tacer, K., Weon, J. L., Potts, M. B., Ou, Y.-H., White, M. A., & Potts, P. R. (2015) · Cell · doi:10.1016/j.cell.2015.01.034 · Cited by 389 · see citing works
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386 · see citing works
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective
Bourdon, J., Surget, S., & Khoury, M. P. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s53876 · Cited by 380 · see citing works
Middleton, G., Silcocks, P., Cox, T. F., Valle, J. W., Wadsley, J., PROPPER, D. J., Coxon, F. Y., Ross, P. J., Madhusudan, S., Roques, T. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70236-0 · Cited by 380 · see citing works
Welters, M. J. P., Kenter, G. G., Piersma, S. J., Vloon, A. P. G., Löwik, M. J. G., der Meer, D. M. A. B.-V., Drijfhout, J. W., Valentijn, A. R. P. M., Wafelman, A. R., Oostendorp, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1880 · Cited by 374 · see citing works
van der Bruggen, P., Bastin, J. M., Gajewski, T. F., et al. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241218 · Cited by 372 · see citing works
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368 · see citing works
Regulation of human telomerase in homeostasis and disease
Roake, C. M., & Artandi, S. E. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0234-z · Cited by 341 · see citing works
Bentzen, A. K., Marquard, A. M., Lyngaa, R., Saini, S. K., Ramskov, S., Donia, M., Such, L., Furness, A. J. S., McGranahan, N., Rosenthal, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3662 · Cited by 332 · see citing works
Human Papillomavirus Vaccines: An Updated Review
Cheng, L., Wang, Y., & Du, J. (2020) · Vaccines · doi:10.3390/vaccines8030391 · Cited by 330 · see citing works
Wheatley, S., & Altieri, D. (2019) · Journal of Cell Science · doi:10.1242/jcs.223826 · Cited by 328 · see citing works
Cooper, C., Davis, H. L., Morris, M. L., Efler, S. M., Adhami, M., KRIEG, A. M., Cameron, D. W., & Heathcote, J. (2004) · Journal of Clinical Immunology · doi:10.1007/s10875-004-6244-3 · Cited by 327 · see citing works
Pmel17 initiates premelanosome morphogenesis within multivesicular bodies
Berson, J. F., Harper, D. C., Tenza, D., Raposo, G., & Marks, M. S. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.11.3451 · Cited by 326 · see citing works
Heterogeneity in the Differentiation and Function of CD8+ T Cells
Mittrücker, H.-W., Visekruna, A., & Huber, M. (2014) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-014-0293-y · Cited by 325 · see citing works
Emerging Concepts and Technologies in Vaccine Development
Brisse, M. E., Vrba, S. M., Kirk, N. M., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 325 · see citing works
Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012142 · Cited by 314 · see citing works
Plaen, E. D., Lurquin, C., Pel, A. V., Mariamé, B., Szikora, J., Wölfel, T., Sibille, C., Chomez, P., & Boon, T. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.7.2274 · Cited by 309 · see citing works
FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution
Newman, A. M., Bratman, S. V., Stehr, H., Lee, L. J., Liu, C. L., Diehn, M., & Alizadeh, A. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu549 · Cited by 304 · see citing works
Berd, D., Maguire, H. C., Jr., McCue, P. A., et al. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1858 · Cited by 300 · see citing works
Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S. S. W., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02031 · Cited by 287 · see citing works
Immunotherapy Against HPV16/18 Generates Potent T H 1 and Cytotoxic Cellular Immune Responses
Bagarazzi, M. L., Yan, J., Morrow, M. P., Shen, X., Parker, R. L., Lee, J. C., Giffear, M., Pankhong, P., Khan, A. S., Broderick, K. E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004414 · Cited by 282 · see citing works
DNA vaccine for cancer immunotherapy
Yang, B. K., Jeang, J., Yang, A. D., Wu, T. ‐., & Hung, C. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.980686 · Cited by 276 · see citing works
Harris, J. E., Ryan, L., Hoover, H. C., Stuart, R. K., Oken, M. M., Benson, A. B., Mansour, E., Haller, D. G., Manola, J., & Hanna, M. G. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.148 · Cited by 273 · see citing works
Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
Leao, R. R. N., Apolónio, J. D., Lee, D., Figueiredo, A., Tabori, U. Y., & Castelo‐Branco, P. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0422-8 · Cited by 266 · see citing works
Le, D. T., Picozzi, V. J., Ko, A. H., Wainberg, Z. A., Kindler, H. L., Wang‐Gillam, A., Oberstein, P. E., Morse, M. A., Zeh, H. J., Weekes, C. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2992 · Cited by 266 · see citing works
Miles, D. W., Roche, H. H., Martín, M., Perren, T. J., Cameron, D., Glaspy, J. A., Dodwell, D., Parker, J., Mayordomo, J. I., Tres, A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0307 · Cited by 264 · see citing works
The MAGE protein family and cancer
Weon, J. L., & Potts, P. R. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.08.002 · Cited by 257 · see citing works
Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 257 · see citing works
Li, F., Aljahdali, I. A. M., & Ling, X. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1362-1 · Cited by 251 · see citing works
CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract.
Schwartz, D. A., Quinn, T. J., Thorne, P. S., Sayeed, S., Yi, A., & KRIEG, A. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119523 · Cited by 250 · see citing works
Mittendorf, E., Clifton, G. T., Holmes, J. P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu211 · Cited by 248 · see citing works
Suschak, J. J., Williams, J. A., & Schmaljohn, C. S. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1330236 · Cited by 240 · see citing works
Regulation of WASH-Dependent Actin Polymerization and Protein Trafficking by Ubiquitination
Hao, Y.-H., Doyle, J., Ramanathan, S., Gomez, T. S., Jia, D., Xu, M., Chen, Z. J., Billadeau, D. D., Rosen, M. K., & Potts, P. R. (2013) · Cell · doi:10.1016/j.cell.2013.01.051 · Cited by 238 · see citing works
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 234 · see citing works
Nuclear and Cytoplasmic Survivin: Molecular Mechanism, Prognostic, and Therapeutic Potential
Stauber, R. H., Mann, W. J., & Knauer, S. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0494 · Cited by 229 · see citing works
Haen, S. P., Loeffler, M. W., Rammensee, H., & Brossart, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0387-x · Cited by 225 · see citing works
Reactivation of Epstein-Barr virus from latency
Amon, W., & Farrell, P. J. (2004) · Reviews in Medical Virology · doi:10.1002/rmv.456 · Cited by 223 · see citing works
Viral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222 · see citing works
Vaccine adjuvant uses of poly-IC and derivatives
Martins, K. A. O., Bavari, S., & Salazar, A. Μ. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.966085 · Cited by 221 · see citing works
Mittendorf, E. A., Lu, B., Melisko, M., Hiller, J. A. P., Bondarenko, I., Brunt, A. M., Sergii, G., Petráková, K., & Peoples, G. E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2867 · Cited by 214 · see citing works
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Lint, S. V., Goyvaerts, C., Maenhout, S. K., Goethals, L., Disy, A., Benteyn, D., Pen, J. J., Bonehill, A., Heirman, C., Breckpot, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2957 · Cited by 210 · see citing works
Engineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208 · see citing works
Hui, E. P., Taylor, G. S., Jia, H., Ma, B. B. Y., Chan, S. L., Ho, R., Wong, W.-L., Wilson, S., Johnson, B. F., Edwards, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2448 · Cited by 207 · see citing works
Sosman, J. A., Unger, J. M., Liu, P. Y., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.072 · Cited by 206 · see citing works
Dréno, B., Thompson, J. F., Smithers, B. M., Santinami, M., Jouary, T., Gutzmer, R., Levchenko, E., Rutkowski, P. L., Grob, J., Korovin, S. I., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30254-7 · Cited by 205 · see citing works
van Poelgeest, M. I. E., Welters, M. J. P., van Esch, E. M. G., Stynenbosch, L. F. M., Kerpershoek, G., van Meerten, E. L. V. P., van den Hende, M., Löwik, M. J. G., der Meer, D. M. A. B.-V., Fathers, L. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-88 · Cited by 194 · see citing works
Recent Progress in GM-CSF-Based Cancer Immunotherapy
Yan, W.-L., Shen, K., Tien, C.-Y., Chen, Y., & Liu, S. (2017) · Immunotherapy · doi:10.2217/imt-2016-0141 · Cited by 194 · see citing works
Taylor, G. S., Jia, H., Harrington, K. J., Lee, L. W., Turner, J., Ladell, K., Price, D. A., Tanday, M., Matthews, J., Roberts, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1122-t · Cited by 189 · see citing works
Speetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185 · see citing works
Fenstermaker, R. A., Ciesielski, M. J., Qiu, J., Yang, N., Frank, C. L., Lee, K. P., Mechtler, L. L., Belal, A., Ahluwalia, M. S., & Hutson, A. D. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1890-x · Cited by 183 · see citing works
PMEL : a pigment cell‐specific model for functional amyloid formation
Watt, B., van Niel, G., Raposo, G., & Marks, M. S. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12067 · Cited by 182 · see citing works
Morton, D. L., Mozzillo, N., Thompson, J. F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8508 · Cited by 177 · see citing works
Keersmaecker, B. D., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 168 · see citing works
Whole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 167 · see citing works
Bonehill, A., Nuffel, A. M. T. V., Corthals, J., Tuyaerts, S., Heirman, C., François, V., Colau, D., van der Bruggen, P., Neyns, B., & Thielemans, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2982 · Cited by 167 · see citing works
Costa, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 162 · see citing works
Wood, L. M., & Paterson, Y. Y. W. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00051 · Cited by 158 · see citing works
Yeast homolog of a cancer‐testis antigen defines a new transcription complex
Kisseleva-Romanova, E., Lopreiato, R., Baudin-Baillieu, A., Rousselle, J., Ilan, L., Hofmann, K., Namane, A., Mann, C., & Libri, D. (2006) · EMBO Journal · doi:10.1038/sj.emboj.7601235 · Cited by 156 · see citing works
Anassi, E., & Ndefo, U. A. (2011) · PubMed · Cited by 154 · see citing works
The problem with neoantigen prediction
(2017) · Nature Biotechnology · doi:10.1038/nbt.3800 · Cited by 148 · see citing works
Morton, D. L., Hsueh, E. C., Essner, R., et al. (2002) · Annals of Surgery · doi:10.1097/00000658-200210000-00006 · Cited by 147 · see citing works
Abrahamsson, P., Lilja, H. G., Falkmer, S., et al. (1988) · The Prostate · doi:10.1002/pros.2990120106 · Cited by 147 · see citing works
Chia, W. K., Wang, W.-W., Teo, M. C. C., Tai, W., Lim, W., Tan, E. H., Leong, S. S., Sun, L., Chen, J. J., Gottschalk, S. M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr341 · Cited by 147 · see citing works
Cunha, A. C., Weigle, B., Kießling, A., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.021 · Cited by 145 · see citing works
Fernandez, J. G., Rodríguez, D. A., Valenzuela, M., Calderón, C. C., Urzúa, U., Munroe, D. J., Rosas, C., David Lemus, A., Díaz‐Valdivia, N., Wright, M. C., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-209 · Cited by 145 · see citing works
Immunotherapy against cancer-related viruses
Tashiro, H., & Brenner, M. K. (2016) · Cell Research · doi:10.1038/cr.2016.153 · Cited by 143 · see citing works
Leffers, N., Lambeck, A. J. A., Gooden, M. J. M., Hoogeboom, B. N., Wolf, R., Hamming, I. L. E., Hepkema, B. G., Willemse, P. H. B., Molmans, B. H. W., Hollema, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24597 · Cited by 141 · see citing works
Hanna, M. G., Hoover, H. C., Vermorken, J. B., et al. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00485-0 · Cited by 138 · see citing works
Morelli, A. B., Becher, D., Koernig, S., Silva, A., Drane, D. P., & Maraskovsky, E. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.040857-0 · Cited by 134 · see citing works
Latest developments in MUC1 immunotherapy
Taylor‐Papadimitriou, J., Burchell, J., Graham, R. A., & Beatson, R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170400 · Cited by 133 · see citing works
van Doorn, E., Liu, H., Huckriede, A. L. W., & Hak, E. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1071455 · Cited by 132 · see citing works
NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline
Schenck, R. O., Lakatos, E., Gatenbee, C., Graham, T. A., & Anderson, A. R. A. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2876-4 · Cited by 130 · see citing works
Regression of Human Papillomavirus Intraepithelial Lesions Is Induced by MVA E2 Therapeutic Vaccine
Rosales, R., López‐Contreras, M., Rosales, C., Magallanes-Molina, J.-R., Gonzalez-Vergara, R., Arroyo-Cazarez, J. M., Ricardez-Arenas, A., del Follo-Valencia, A., Padilla-Arriaga, S., Guerrero, M. V., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.024 · Cited by 127 · see citing works
Lennerz, V., Groß, S., Gallerani, E., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1516-5 · Cited by 126 · see citing works
Aggarwal, C., Cohen, R., Morrow, M., Kraynyak, K., Sylvester, A., Knoblock, D., Bauml, J., Weinstein, G., Lin, A., Boyer, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1763 · Cited by 124 · see citing works
Virus‐like particles for vaccination against cancer
Mohsen, M. O., Speiser, D. E., Knuth, A. K., & Bachmann, M. F. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1579 · Cited by 124 · see citing works
Oncogenic Potential of Hepatitis C Virus Proteins
Banerjee, A. K., Ray, R. B., & Ray, R. (2010) · Viruses · doi:10.3390/v2092108 · Cited by 123 · see citing works
Telomerase-Targeted Cancer Immunotherapy
Mizukoshi, E., & Kaneko, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081823 · Cited by 123 · see citing works
Peptide vaccines in cancer — old concept revisited
Kumai, T., Kobayashi, H., Harabuchi, Y., & Celis, E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.11.001 · Cited by 120 · see citing works
Synthesis and assembly of infectious bovine papillomavirus particles in vitro
Zhou, J., Stenzel, D. J., Sun, X.-Y., et al. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-4-763 · Cited by 119 · see citing works
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour, H. M., Storkus, W. J., Brusić, V., et al. (2000) · PubMed · Cited by 118 · see citing works
Adjuvant Activity of Cytokines
Tovey, M. G., & Lallemand, C. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-585-9_19 · Cited by 118 · see citing works
Zimber‐Strobl, U., Kempkes, B., Marschall, G., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01098.x · Cited by 115 · see citing works
Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
Nunberg, J. H., DOYLE, M. V., York, S. M., et al. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4240 · Cited by 113 · see citing works
Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1
Nicholaou, T., Ebert, L. M., Davis, I. D., Robson, N. C., Klein, O., Maraskovsky, E., Chen, W., & Cebon, J. S. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2006.01446.x · Cited by 111 · see citing works
CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update
Lee, G. H., & Lim, S. G. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1908133 · Cited by 107 · see citing works
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B. N., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 97 · see citing works
Emerging Roles of Human Prostatic Acid Phosphatase
Kong, H. Y., & Byun, J. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.095 · Cited by 96 · see citing works
Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells
Saini, S. K., Tamhane, T., Anjanappa, R., Saikia, A., Ramskov, S., Donia, M., Svane, I. M., Jakobsen, S. N., García-Alai, M., Zacharias, M., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau9039 · Cited by 96 · see citing works
Solving the Telomere Replication Problem
Maestroni, L., Matmati, S., & Coulon, S. (2017) · Genes · doi:10.3390/genes8020055 · Cited by 94 · see citing works
Human Prostatic Acid Phosphatase: Structure, Function and Regulation
Muniyan, S., Chaturvedi, N. K., Dwyer, J., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510438 · Cited by 93 · see citing works
Wilson, J. B., Manet, É., Gruffat, H., Busson, P., Blondel, M., & Fåhræus, R. (2018) · Cancers · doi:10.3390/cancers10040109 · Cited by 93 · see citing works
MPL Adjuvant Contains Competitive Antagonists of Human TLR4
Wang, Y., Bazin, H. G., Evans, J. T., Casella, C. R., & Mitchell, T. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577823 · Cited by 92 · see citing works
Lilleby, W. A., Gaudernack, G., Brunsvig, P. F., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1994-y · Cited by 91 · see citing works
van der Burg, S. H., Menon, A. G., Redeker, A., Bonnet, M.-C., Drijfhout, J. W., Tollenaar, R. A. �. �., van de Velde, C. J. �., Moingeon, P. E., Kuppen, P. J. K., Offringa, R., et al. (2002) · PubMed · Cited by 90 · see citing works
Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
Pallerla, S., Abdul, A. U. R. M., Comeau, J. M., & Jois, S. D. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020779 · Cited by 88 · see citing works
Gupta, R., Leon, F., Rauth, S., Batra, S. K., & Ponnusamy, M. P. (2020) · Cells · doi:10.3390/cells9020446 · Cited by 86 · see citing works
Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer
Pilarsky, C. P., Schmidt, U., Eißrich, C., Stade, J., Froschermaier, S. E., Haase, M., Faller, G., Kirchner, T., & Wirth, M. P. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980701)36:2 · Cited by 84 · see citing works
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L.-P., Yan, L., Long, M. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 84 · see citing works
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T., van der Hoeven, J. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4772 · Cited by 83 · see citing works
Recommendations for performance optimizations when using GATK3.8 and GATK4
Heldenbrand, J. R., Baheti, S., Bockol, M. A., Drucker, T., Hart, S. N., Hudson, M. E., Iyer, R. K., Kalmbach, M. T., Kendig, K. I., Klee, E. W., et al. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3169-7 · Cited by 82 · see citing works
Host Responses from Innate to Adaptive Immunity after Vaccination: Molecular and Cellular Events
Kang, S., & Compans, R. W. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0015-1 · Cited by 79 · see citing works
QS-21: A Potent Vaccine Adjuvant
Tuo, D. Z. W. (2015) · Natural Products Chemistry & Research · doi:10.4172/2329-6836.1000e113 · Cited by 77 · see citing works
MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development
Gjerstorff, M. F., Kock, K., Nielsen, O., & Ditzel, H. J. (2007) · Human Reproduction · doi:10.1093/humrep/del494 · Cited by 71 · see citing works
Age-Related Changes in Tissue Levels of Prostatic Acid Phosphatase and Prostate Specific Antigen
Goldfarb, D. A., Stein, B. S., Shamszadeh, M., et al. (1986) · The Journal of Urology · doi:10.1016/s0022-5347(17)45310-9 · Cited by 71 · see citing works
Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
Caldeira, J. C., Perrine, M. F., Pericle, F., & Cavallo, F. (2020) · Viruses · doi:10.3390/v12050488 · Cited by 70 · see citing works
Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2709 · Cited by 66 · see citing works
Overexpressed oncogenic tumor-self antigens
Bright, R. K., Bright, J. D., & Byrne, J. A. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29475 · Cited by 65 · see citing works
Kantoff, P. W., Gulley, J. L., & Pico-Navarro, C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.7748 · Cited by 65 · see citing works
Subunit structure of human prostatic acid phosphatase
Luchter-Wasyl, E., & Ostrowski, W. (1974) · Biochimica et Biophysica Acta (BBA) - Protein Structure · doi:10.1016/0005-2795(74)90008-7 · Cited by 62 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [64]Higano C. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) Proceedings of the 2009 Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Orlando, FL, USA 26–28 February 2009
- [66]Small E. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) Proceedings of the 2009 Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Orlando, FL, USA 26–28 February 2009
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works
- Authors
- Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Cruz, Jazmina L. G.
- ORCID
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-05-20
- Volume
- 9
- Issue
- 5
- Pages
- 535
- ISSN
- 2076-393X (ISSN-L)
- PMC
- PMC8160852
- OpenAlex
- W3165800301
- Cited by
- 76
- References
- 234
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 15 · 2023: 22 · 2022: 12 · 2021: 4
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vaccines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Garnett Passe and Rodney Williams Memorial Foundation (2019_CG_Gonzalez Cruz_Perry)
- PA Research Foundation (Panizza_Cruz_2021)
- National Health and Medical Research Council (Investigator grant_Frazer_2020)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Keywords
- cancer vaccines, tumor antigens, vaccine delivery, dendritic cell vaccine, nanoliposomes, tumor immune evasion, antitumor immunity, combination immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
